lenalidomide has been researched along with Blood Clot in 25 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (32.00) | 29.6817 |
| 2010's | 12 (48.00) | 24.3611 |
| 2020's | 5 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mai, EK | 1 |
| Binder, M; Buadi, FK; Charalampous, C; Dingli, D; Dispenzieri, A; Fonder, AL; Gertz, MA; Goel, U; Gonsalves, W; Hayman, SR; Hobbs, MA; Hwa, YL; Kapoor, P; Kourelis, T; Kumar, S; Kyle, RA; Lacy, MQ; Leung, N; Lin, Y; Rajkumar, SV; Warsame, R | 1 |
| Bye, AP; Gibbins, JM; Grech, H; Khan, D; Kriek, N; Laffan, M; Mitchell, JL; Ramasamy, K; Rana, RH; Sage, T; Shapiro, S; Thakurta, A; Unsworth, AJ | 1 |
| Bradbury, CA; Cairns, DA; Child, JA; Cook, G; Craig, Z; Davies, FE; Drayson, MT; Gregory, WM; Hockaday, A; Jackson, GH; Jenner, MW; Jones, JR; Kaiser, MF; Morgan, GJ; Owen, RG; Paterson, A; Pawlyn, C | 1 |
| Atherton, PJ; Bartlett, NL; Blum, KA; Dueck, AC; Flowers, CR; Habermann, TM; Jung, SH; Leonard, JP; Novotny, PJ; Pitcher, BN; Tan, A; Thanarajasingam, G; Witzig, TE | 1 |
| Ayyalu, TK; Issa, M | 1 |
| Aldaoud, A; Harde, J; Knauf, W; Losem, C; Mittermueller, J; Neise, M; Niemeier, B; Potthoff, K; Trarbach, T | 1 |
| Andresen, S; Ann Karam, M; Baz, R; Bruening, K; Dean, R; Faiman, B; Habecker, B; Hamilton, K; Hussein, MA; Kalaycio, M; Knight, R; Lazaryan, A; Reed, J; Reu, FJ; Sobecks, R; Srkalovic, G; Sweetenham, JW; Waksman, J; Zeldis, JB | 1 |
| Bartlett, NL; Blum, KA; Cheson, BD; Czuczman, M; Giguere, JK; Johnson, J; Jung, SH; Leonard, JP; Pitcher, BN | 1 |
| Leebeek, FW | 1 |
| Chalayer, E; Chapelle, C; Elalamy, I; Laporte, S; Leleu, X; Tardy, B | 1 |
| Cornell, RF; Gailani, D; Garcia, D; Laubach, J; Li, W; Maglio, ME; Moslehi, J; Richardson, PG | 1 |
| Gieseler, F | 1 |
| Paydas, S | 1 |
| Martínez-Baños, DM; Niesvizky, R | 1 |
| Coleman, M; Mark, T; Niesvizky, R | 1 |
| Kristinsson, SY | 1 |
| Brioli, A; Cavo, M; Pantani, L; Tacchetti, P; Zamagni, E; Zannetti, B | 1 |
| Gil, L; Komarnicki, M; Rupa-Matysek, J | 1 |
| Braggio, E; Cesarman-Maus, G; Fonseca, R | 1 |
| Alexander, M; Kirsa, S; Lingaratnam, S; Mellor, JD; Teoh, KC | 1 |
| Barlogie, B; Crowley, J; Durie, BG; Hussein, MA; McCoy, J; Zonder, JA | 1 |
| Carwile, J; El Rassi, FA; Tam, CS; Verstovsek, S | 1 |
| Christos, P; Coleman, M; De Sancho, M; Furst, J; Jalbrzikowski, J; Jayabalan, D; Leonard, J; Mark, T; Martínez-Baños, D; Mazumdar, M; Niesvizky, R; Pearse, R; Pekle, K; Zafar, F | 1 |
| Anderson, KC; Attal, M; Barlogie, B; Belch, A; Bladé, J; Boccadoro, M; Bringhen, S; Cavo, M; Dimopoulos, MA; Durie, BG; Harousseau, J; Hussein, MA; Joshua, D; Knop, S; Kyle, R; Lonial, S; Ludwig, H; Morgan, GJ; Niesvizky, R; Orlowski, RZ; Palumbo, A; Rajkumar, SV; Richardson, PG; San Miguel, J; Sezer, O; Shimizu, K; Sonneveld, P; Vesole, D; von Lilienfeld-Toal, M; Waage, A; Weber, D; Westin, J; Zangari, M; Zonder, JA | 1 |
7 review(s) available for lenalidomide and Blood Clot
| Article | Year |
|---|---|
Update of thrombosis in multiple myeloma.
Topics: Anticoagulants; Antineoplastic Agents; Aspirin; Heparin, Low-Molecular-Weight; Humans; Lenalidomide; Multiple Myeloma; Thalidomide; Thrombosis; Warfarin | 2016 |
Cardiovascular and Thrombotic Complications of Novel Multiple Myeloma Therapies: A Review.
Topics: Antineoplastic Agents; Cardiovascular Diseases; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Proteasome Inhibitors; Risk Factors; Thalidomide; Thromboembolism; Thrombosis | 2017 |
Pathophysiological considerations to thrombophilia in the treatment of multiple myeloma with thalidomide and derivates.
Topics: Antineoplastic Agents; Blood Coagulation; Fibrinolytic Agents; Humans; Lenalidomide; Multiple Myeloma; Platelet Activation; Risk Assessment; Thalidomide; Thrombin; Thrombophilia; Thrombosis; Treatment Outcome; von Willebrand Factor | 2008 |
Thrombosis in multiple myeloma.
Topics: Humans; Lenalidomide; Multiple Myeloma; Risk Factors; Thalidomide; Thrombosis; Venous Thromboembolism | 2010 |
[Thrombotic complications following the treatment of multiple myeloma with new agents].
Topics: Anthracyclines; Anticoagulants; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide; Thrombosis | 2011 |
Thrombosis in multiple myeloma (MM).
Topics: Anthracyclines; Antineoplastic Agents, Hormonal; Dexamethasone; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Proteasome Inhibitors; Thalidomide; Thrombosis | 2012 |
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
Topics: Antineoplastic Agents; Aspirin; Heparin, Low-Molecular-Weight; Humans; International Normalized Ratio; Lenalidomide; Multiple Myeloma; Premedication; Risk Assessment; Risk Factors; Thalidomide; Thrombosis; Venous Thromboembolism; Warfarin | 2008 |
5 trial(s) available for lenalidomide and Blood Clot
| Article | Year |
|---|---|
Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Incidence; Kaplan-Meier Estimate; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisolone; Progression-Free Survival; Risk Assessment; Thalidomide; Thrombophilia; Thrombosis; Transplantation, Autologous; Venous Thromboembolism; Vincristine | 2020 |
Longitudinal Toxicity over Time (ToxT) analysis to evaluate tolerability: a case study of lenalidomide in the CALGB 50401 (Alliance) trial.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Drug Tolerance; Fatigue; Hematologic Neoplasms; Humans; Infusions, Intravenous; Lenalidomide; Lymphoma, Follicular; Neutropenia; Rituximab; Thrombosis | 2020 |
Mature results of MM-011: a phase I/II trial of liposomal doxorubicin, vincristine, dexamethasone, and lenalidomide combination therapy followed by lenalidomide maintenance for relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dexamethasone; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Hematologic Diseases; Humans; Infection Control; Kaplan-Meier Estimate; Karyotyping; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Proportional Hazards Models; Remission Induction; Salvage Therapy; Thalidomide; Thrombosis; Treatment Outcome; Vincristine | 2014 |
Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Disease Progression; Disease-Free Survival; Female; Heparin; Humans; Kaplan-Meier Estimate; Lenalidomide; Lymphoma, Follicular; Male; Middle Aged; Neoplasm Recurrence, Local; Risk Factors; Rituximab; Thalidomide; Thrombosis; Treatment Outcome | 2015 |
Tailored thromboprophylaxis for patients with multiple myeloma treated by IMIDs.
Topics: Aspirin; Chemoprevention; Humans; Lenalidomide; Multiple Myeloma; Thalidomide; Thrombosis | 2008 |
13 other study(ies) available for lenalidomide and Blood Clot
| Article | Year |
|---|---|
Vascular thrombotic events in the era of modern myeloma therapy.
Topics: Anticoagulants; Aspirin; Heparin, Low-Molecular-Weight; Humans; Lenalidomide; Multiple Myeloma; Thrombosis | 2022 |
Thrombosis in multiple myeloma: Risk estimation by induction regimen and association with overall survival.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Multiple Myeloma; Thromboembolism; Thrombosis | 2023 |
Multiple myeloma and its treatment contribute to increased platelet reactivity.
Topics: Humans; Lenalidomide; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Pilot Projects; Thrombosis | 2023 |
Lenalidomide-associated arterial thrombosis in a patient with JAK2 positive atypical myeloproliferative neoplasm.
Topics: Aged; Bone Marrow Neoplasms; Fatal Outcome; Female; Humans; Immunologic Factors; Janus Kinase 2; Lenalidomide; Myeloproliferative Disorders; Thalidomide; Thrombosis | 2017 |
Lenalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma: Final results of a non-interventional study and comparison with the pivotal phase 3 clinical trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Dexamethasone; Disease Progression; Febrile Neutropenia; Female; Humans; Infections; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Renal Insufficiency; Thrombosis | 2018 |
Does the choice of thrombotic prophylactic drug depend on the known risk factors of patients with multiple myeloma in clinical practice?
Topics: Aged; Angiogenesis Inhibitors; Anticoagulants; Aspirin; Female; Heparin, Low-Molecular-Weight; Humans; Lenalidomide; Male; Multiple Myeloma; Risk Factors; Thalidomide; Thrombosis; Vitamin K | 2016 |
Aspirin as thromboprophylaxis in myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aspirin; Chemoprevention; Humans; Lenalidomide; Multiple Myeloma; Thalidomide; Thrombosis | 2008 |
Novel agents in myeloma: an exciting saga.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Survival Analysis; Thalidomide; Thrombosis | 2009 |
Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis.
Topics: Activated Protein C Resistance; Aged; Anticoagulants; Aspirin; Boronic Acids; Bortezomib; Dexamethasone; Humans; Immunologic Factors; International Normalized Ratio; Lenalidomide; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Risk Factors; Thalidomide; Thrombosis; Venous Thromboembolism; Warfarin | 2011 |
Thromboprophylaxis prescribing and thrombotic event rates in multiple myeloma patients treated with lenalidomide or thalidomide at a specialist cancer hospital.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Anticoagulants; Aspirin; Cancer Care Facilities; Enoxaparin; Female; Fibrinolytic Agents; Follow-Up Studies; Humans; Incidence; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Practice Patterns, Physicians'; Prognosis; Retrospective Studies; Specialization; Thalidomide; Thrombosis; Warfarin | 2013 |
Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aspirin; Dexamethasone; Fibrinolytic Agents; Humans; Lenalidomide; Multiple Myeloma; Risk Factors; Thalidomide; Thromboembolism; Thrombosis; Treatment Outcome | 2006 |
Thrombosis of the corpora cavernosa complicating lenalidomide therapy of myelofibrosis.
Topics: Aged; Humans; Lenalidomide; Male; Penis; Primary Myelofibrosis; Thalidomide; Thrombosis | 2008 |
Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Aspirin; Drug Therapy, Combination; Female; Heparin, Low-Molecular-Weight; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Retrospective Studies; Thalidomide; Thrombosis | 2007 |